KDR and hereditary clear cell renal cell carcinoma: For instance, Cabozantinib can inhibit the kinase activity of VEGFR, MET, and other receptors, and is utilized in the treatment of thyroid adenocarcinoma (101) and renal cell carcinoma (102).